Home
    • Plans Blog Contact
    Trinity Biotech plc logo

    Trinity Biotech plc

    TRIB
    Last price US$8.45
    Market cap US$3.0b
    12M price change N/A
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    IQVIA Holdings IncIQV Industry peer Agilent Technologies IncA Industry peer Thermo Fisher Scientific IncTMO Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Trinity Biotech plc Overview

    Industry: Diagnostics & Research

    Sector: Healthcare

    Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland. Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests a Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Trinity Biotech plc into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Jun 29, 2026

    Quarterly result summary

    Exhibit 99.1 Contact: Trinity Biotech plc Paul Murphy (353)-1-2769800 RedChip Companies Inc. Dave Gentry, CEO (1)-407-644-4256 (1)-800-RED-CHIP (733-2447) [email protected] Trinity Biotech Terminates Standby Equity Purchase Agreement with Yorkville DUBLIN, Ire...

    What changed

    • Review the SEC source filing for the full reported results and management commentary.

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 6-K Jul 22, 2026 SEC filing 6-K Jul 22, 2026 SEC filing EXHIBIT 99.1 Jul 22, 2026 SEC filing 6-K Jul 02, 2026 SEC filing 6-K Jun 30, 2026 SEC filing 6-K Jun 29, 2026 SEC filing 6-K Jun 23, 2026 Earnings release EXHIBIT 99.1 Jun 18, 2026 SEC filing 6-K May 06, 2026 Earnings release EXHIBIT 99.1 May 06, 2026

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 0.00/5
    Trinity Biotech plc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Diagnostics & Research industry , IQVIA Holdings Inc , Agilent Technologies Inc , Thermo Fisher Scientific Inc are companies with high ratings.

    Return on Equity

    Score 1.96/5
    Trinity Biotech plc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Trinity Biot... TRIB US$3.0b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 2.21/5
    Trinity Biotech plc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Trinity Biot... TRIB US$3.0b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Diagnostics & Research industry , IQVIA Holdings Inc , Agilent Technologies Inc , Thermo Fisher Scientific Inc are companies with high ratings.

    Leverage

    Score 1.01/5
    Trinity Biotech plc registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    Trinity Biot... TRIB US$3.0b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Trinity Biotech plc logo

    Trinity Biotech plc

    US$8.45

    US$3.0b

    2383.82%

    N/A